Milestone Pharmaceuticals/MIST

$2.16

-1.82%
-
1D1W1MYTD1YMAX

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Ticker

MIST

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Oliveto

Employees

39

Headquarters

Montreal, Canada

MIST Metrics

BasicAdvanced
$70.65M
Market cap
-
P/E ratio
-$1.38
EPS
1.83
Beta
-
Dividend rate

What the Analysts think about MIST

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
397.69% upside
High $25.00
Low $3.00
$2.16
Current price
$10.75
Average price target

MIST Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-15M
-6.25%
Profit margin
0%
-

MIST Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.38%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.31
-$0.35
-$0.37
-$0.35
-
Expected
-$0.34
-$0.40
-$0.39
-$0.38
-$0.35
Surprise
-7.46%
-12.06%
-4.15%
-8.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Milestone Pharmaceuticals stock

Buy or sell Milestone Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing